Determining therapeutic potential of BDNF in delaying the onset and progression of Spinocerebellar ataxia type 1 (SCA1)
Grant Project Details:
Awardee:
Marija Cvetanovic, PhD
Timeframe:
2018-2020
Location:
University of Minnesota | Minneapolis, MN
Amount:
$250,000
Status:
In Process
Explore all RMM grants awarded since inception
Grant timeline: proposal, updates, reports
Grant Location
University of Minnesota
2101 6th Street SE
Minneapolis, MN 55455
Grant Description
Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease with no available therapies. This proposal will determine therapeutic potential of a brain-derived neurotrophic factor (BDNF) to regenerate communication between cells in the brain, prevent neuronal loss, and delay disease onset and progression in SCA1. Completion of this research will provide a foundation for developing preventive and therapeutic interventions for SCA1 and other neurodegenerative diseases.
Using RMM funding we were able to determine that treatment with neurotrophic factor BDNF delays disease onset both at the behavioral level as well as at the level of tissue and neuronal pathology. We are currently testing whether BDNF can ameliorate disease severity after the onset of symptoms.
Grant Awardee Biography
Dr. Cvetanovic is an Assistant Professor in the Department of Neuroscience at the University of Minnesota. Her research focuses on how differend kinds of brain cells and their interactions influence the onset and progression of neurodegenerative diseases. In her laboratory, she also focuses on providing the next generation of scientists with the training and support they need to succeed as independent investigators.